Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo

Chronic Obstructive Pulmonary Disease poses a major health challenge globally and is currently the third leading cause of death worldwide, resulting in approximately 3.23 million deaths annually. The impact of COPD is particularly pronounced in low- and middle-income countries where healthcare resources may be limited. COPD is characterized by a progressive decline in lung function, frequent exacerbations, and high morbidity and mortality rates. Exacerbations, which are acute worsening events of respiratory symptoms, play a critical role in disease progression. Hospitalized severe exacerbations markedly increase the risk of further exacerbations, a rapid decline in health status, and high short-term mortality rates. Roughly 20% of patients at GOLD stage 2 experience frequent exacerbations necessitating additional interventions, with risk increasing in GOLD stages 3 and 4.

Recent clinical guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) emphasize a multidimensional assessment, incorporating lung function, prior exacerbation history, and patient-reported symptoms to guide treatment. The overall goal of COPD pharmacologic therapy is to reduce symptoms (including dyspnea), prevent exacerbations, improve exercise tolerance, and enhance quality of life. Triple inhaled therapy, consisting of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and long-acting β2-agonist (LABA), is recommended for patients in GOLD Group E who continue to experience exacerbations despite dual therapy. This approach has demonstrated beneficial effect in reducing mortality among high-risk, symptomatic COPD patients.

Breztri/Trixeo (BGF) is a fixed-dose triple combination of budesonide (ICS), glycopyrrolate (LAMA), and formoterol fumarate (LABA), administered via a metered dose inhaler utilizing Aerosphere™ delivery technology. BGF received regulatory approval from the FDA in July 2020 and the EMA in December 2020, based on phase III randomized controlled trials (RCTs) that established its efficacy in improving lung function and reducing moderate/severe exacerbations. These trials primarily measured lung function and exacerbation rates and also included secondary endpoints evaluating patient-reported outcomes (PROs). Despite these findings, there is a need for real-world evidence (RWE) to better understand the effectiveness, safety, and patient experience of BGF outside the controlled environment of RCTs.

The importance of capturing PROs-such as the COPD Assessment Test (CAT) and modified Medical Research Council (m-MRC) dyspnea scale-in both clinical trials and real-world studies is increasingly recognized in the literature and reflected in current GOLD recommendations. Observational, patient-centric studies in routine clinical practice can provide complementary insights to RCTs, particularly through direct and timely collection of PRO data. Such studies elucidate the real-life impact of COPD and its management on daily patient functioning and quality of life and are valuable to healthcare payers, practitioners, and patients themselves.

To address gaps in population diversity of earlier RCTs and to better understand the use of BGF in routine medical practice, the iCHOROS study is a non-interventional, prospective, multinational, multicenter observational cohort study designed to document clinical and patient-reported outcomes in COPD patients initiated on BGF. The study includes patients from diverse and often underrepresented regions, such as Latin America (Mexico, Argentina, Colombia, Central America and Caribbean, Costa Rica, Panama), Asia (Taiwan, Philippines, India, Vietnam, Malaysia, Indonesia, Thailand), and the Middle East and Africa (KSA, Kuwait, UAE, Egypt, Jordan). This design supports the collection of more generalizable and globally relevant data.

The primary objective of this study is to estimate the change in COPD health status using the mean change from baseline in CAT score after 12 weeks of BGF treatment. Secondary objectives include evaluating CAT score changes at weeks 26 and 52, determining the proportion of CAT responders at week 12, comparing moderate and severe exacerbation rates before and after BGF initiation, and describing patient satisfaction with inhaler devices across all visits. Additional endpoints include global impression of change and severity (PGI-C, PGI-S), BGF treatment patterns and reasons for discontinuation, changes in m-MRC score and spirometry parameters (FEV1, FVC, FEV1/FVC), as well as exploratory assessments of baseline clinical characteristics and cardiovascular events.

In accordance with real-world clinical practice, patient follow-up visits will occur at baseline, week 12, week 26, and week 52, with all treatments and diagnostic evaluations determined solely by the attending physician and local guidelines. Patients' demographics, vital signs, medical and exacerbation history, and medication use will be recorded at baseline. The decision to initiate BGF and all management is entirely at the physician's discretion, separate from study participation or informed consent. Study participation will cease upon discontinuation of BGF. The data collection is hybrid, using existing medical records and primary data from scheduled visits without altering the standard of care or providing investigational medication. The total duration for each patient is 52 weeks or until discontinuation of BGF, and the overall study timeframe is estimated at 21 months, including interim analyses for CAT score and exacerbation rate results as more than half the population reaches key visits. Overall, the iCHOROS study aims to comprehensively characterize real-world clinical and patient-reported outcomes associated with BGF, thus supporting better clinical decisions and patient-centered care for COPD worldwide.

Plazo: 12 weeks

Mean change from baseline in the COPD Assessment Test (CAT) scores after 12 weeks from treatment initiation

Plazo: 26 Weeks

Mean change from baseline in CAT scores after 26 weeks of treatment

Plazo: 52 weeks

Mean change from baseline in CAT scores after 52 weeks of treatment

Plazo: 12 weeks

Percent of responders of the CAT achieving MCID ≥ 2 after 12 weeks of treatment compared to baseline.

Plazo: Baseline

IQVIA Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)© scores at baseline

Plazo: 12 weeks

IQVIA Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)© scores at 12 weeks

Plazo: 26 Weeks

IQVIA Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)© scores at 26 weeks

Plazo: 52 weeks

IQVIA Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)© scores at 52 weeks.

Plazo: 52 weeks

Mean change from baseline in patient global impression of change (PGI-C) after 52 weeks from treatment initiation

Plazo: 12 weeks

Mean change from baseline in COPD symptoms severity using the patient global impression of severity (PGI-S) after 12 weeks from treatment initiation

Plazo: 26 Weeks

Mean change from baseline in COPD symptoms severity using the patient global impression of severity (PGI-S) after 26 weeks from treatment initiation

Plazo: 52 Weeks

Mean change from baseline in COPD symptoms severity using the patient global impression of severity (PGI-S) after 52 weeks from treatment initiation

Plazo: 12 weeks

Mean change from baseline in mMRC dyspnoea score after 12 weeks from treatment initiation.

Plazo: 26 Weeks

Mean change from baseline in mMRC dyspnoea score (Appendix 6) after 26 weeks from treatment initiation.

Plazo: 52 weeks

Mean change from baseline in mMRC dyspnoea score (Appendix 6) after 52 weeks from treatment initiation.

Real-world, International, Multicentre, Non-interventional, Prospective Cohort to Assess Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo in Routine Care Settings